Hem › Triplenegativ bröstcancer › Maryland › Baltimore
Kliniska studier för Triplenegativ bröstcancer i Baltimore, MD
12 studier för Triplenegativ bröstcancer söker deltagare vid platser i och runt Baltimore (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
RekryterarFas 3
- MedStar Franklin Square Medical Center ( Site 0031), Baltimore
- MedStar Good Samaritan Hospital ( Site 0079), Baltimore
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RekryterarFas 3
- Mercy Medical Center - Baltimore ( Site 0015), Baltimore
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
RekryterarFas 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
RekryterarFas 1
- United Theranostics, Glen Burnie · 9 mi bort
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
RekryterarFas 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RekryterarFas 3
- Sinai Hospital of Baltimore, Inc., Baltimore
- St. Agnes Hospital, Baltimore
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore
- och 1 fler
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
RekryterarFas 2
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RekryterarFas 2/3
- Local Institution - 1035, Baltimore
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
RekryterarFas 1
- United Theranostics, Glen Burnie · 9 mi bort
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
RekryterarFas 1/2
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
RekryterarFas 2
- University of Maryland Medical Center (UMMC), Baltimore
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
RekryterarFas 1
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Triplenegativ bröstcancer-studier i andra städer
- Houston, TX42 studier
- New York City, NY31 studier
- Nashville, TN28 studier
- Los Angeles, CA27 studier
- Boston, MA26 studier
- San Antonio, TX23 studier
- St. Louis, MO21 studier
- Arlington, VA20 studier
- Atlanta, GA20 studier
- Dallas, TX18 studier
- Chicago, IL16 studier
- Columbus, OH16 studier
Andra studier i Baltimore
- Icke-småcellig lungcancer60 studier
- Bröstcancer47 studier
- Prostatacancer43 studier
- Lungcancer40 studier
- Cancer (alla typer)37 studier
- Bukspottkörtelcancer31 studier
- Kolorektal cancer31 studier
- Metastaserande cancer28 studier
- Övervikt26 studier
- Blåscancer24 studier
- Hjärtsvikt24 studier
- Äggstockscancer22 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.